107 related articles for article (PubMed ID: 15331430)
1. ATP-binding cassette transporter G8 gene as a determinant of apolipoprotein B-100 kinetics in overweight men.
Chan DC; Watts GF; Barrett PH; Whitfield AJ; van Bockxmeer FM
Arterioscler Thromb Vasc Biol; 2004 Nov; 24(11):2188-91. PubMed ID: 15331430
[TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein B-100 kinetics and static plasma indices of triglyceride-rich lipoprotein metabolism in overweight men.
Chan DC; Watts GF; Ng TW; Uchida Y; Sakai N; Yamashita S; Barrett PH
Clin Biochem; 2005 Sep; 38(9):806-12. PubMed ID: 15992790
[TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration.
Chan DC; Watts GF; Redgrave TG; Mori TA; Barrett PH
Metabolism; 2002 Aug; 51(8):1041-6. PubMed ID: 12145779
[TBL] [Abstract][Full Text] [Related]
4. Variation in Niemann-Pick C1-like 1 gene as a determinant of apolipoprotein B-100 kinetics and response to statin therapy in centrally obese men.
Chan DC; Watts GF; Wang J; Hegele RA; van Bockxmeer FM; Barrett PH
Clin Endocrinol (Oxf); 2008 Jul; 69(1):45-51. PubMed ID: 18031309
[TBL] [Abstract][Full Text] [Related]
5. Very low density lipoprotein metabolism and plasma adiponectin as predictors of high-density lipoprotein apolipoprotein A-I kinetics in obese and nonobese men.
Chan DC; Barrett PH; Ooi EM; Ji J; Chan DT; Watts GF
J Clin Endocrinol Metab; 2009 Mar; 94(3):989-97. PubMed ID: 19116237
[TBL] [Abstract][Full Text] [Related]
6. Effects of ApoE genotype on ApoB-48 and ApoB-100 kinetics with stable isotopes in humans.
Welty FK; Lichtenstein AH; Barrett PH; Jenner JL; Dolnikowski GG; Schaefer EJ
Arterioscler Thromb Vasc Biol; 2000 Jul; 20(7):1807-10. PubMed ID: 10894821
[TBL] [Abstract][Full Text] [Related]
7. Plasma markers of cholesterol homeostasis and apolipoprotein B-100 kinetics in the metabolic syndrome.
Chan DC; Watts GF; Barrett PH; O'Neill FH; Thompson GR
Obes Res; 2003 Apr; 11(4):591-6. PubMed ID: 12690090
[TBL] [Abstract][Full Text] [Related]
8. Hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 studied with a stable isotope technique in men with visceral obesity.
Riches FM; Watts GF; Naoumova RP; Kelly JM; Croft KD; Thompson GR
Int J Obes Relat Metab Disord; 1998 May; 22(5):414-23. PubMed ID: 9622338
[TBL] [Abstract][Full Text] [Related]
9. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes.
Welty FK; Lichtenstein AH; Barrett PH; Dolnikowski GG; Schaefer EJ
Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1703-7. PubMed ID: 15242863
[TBL] [Abstract][Full Text] [Related]
10. Effect of ezetimibe on the in vivo kinetics of apoB-48 and apoB-100 in men with primary hypercholesterolemia.
Tremblay AJ; Lamarche B; Cohn JS; Hogue JC; Couture P
Arterioscler Thromb Vasc Biol; 2006 May; 26(5):1101-6. PubMed ID: 16528005
[TBL] [Abstract][Full Text] [Related]
11. Human apolipoprotein (Apo) B-48 and ApoB-100 kinetics with stable isotopes.
Welty FK; Lichtenstein AH; Barrett PH; Dolnikowski GG; Schaefer EJ
Arterioscler Thromb Vasc Biol; 1999 Dec; 19(12):2966-74. PubMed ID: 10591677
[TBL] [Abstract][Full Text] [Related]
12. Apolipoproteins C-III and A-V as predictors of very-low-density lipoprotein triglyceride and apolipoprotein B-100 kinetics.
Chan DC; Watts GF; Nguyen MN; Barrett PH
Arterioscler Thromb Vasc Biol; 2006 Mar; 26(3):590-6. PubMed ID: 16410456
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity.
Chan DC; Watts GF; Barrett PH; Mori TA; Beilin LJ; Redgrave TG
J Clin Endocrinol Metab; 2002 May; 87(5):2283-9. PubMed ID: 11994377
[TBL] [Abstract][Full Text] [Related]
14. Reduction in visceral adipose tissue is associated with improvement in apolipoprotein B-100 metabolism in obese men.
Riches FM; Watts GF; Hua J; Stewart GR; Naoumova RP; Barrett PH
J Clin Endocrinol Metab; 1999 Aug; 84(8):2854-61. PubMed ID: 10443691
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein A-I, B-100, and B-48 metabolism in subjects with chronic kidney disease, obesity, and the metabolic syndrome.
Batista MC; Welty FK; Diffenderfer MR; Sarnak MJ; Schaefer EJ; Lamon-Fava S; Asztalos BF; Dolnikowski GG; Brousseau ME; Marsh JB
Metabolism; 2004 Oct; 53(10):1255-61. PubMed ID: 15375779
[TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein B-100 and apoA-II kinetics as determinants of cellular cholesterol efflux.
Chan DC; Hoang A; Barrett PH; Wong AT; Nestel PJ; Sviridov D; Watts GF
J Clin Endocrinol Metab; 2012 Sep; 97(9):E1658-66. PubMed ID: 22745238
[TBL] [Abstract][Full Text] [Related]
17. Lipoprotein Metabolism in APOB L343V Familial Hypobetalipoproteinemia.
Hooper AJ; Heeks L; Robertson K; Champain D; Hua J; Song S; Parhofer KG; Barrett PH; van Bockxmeer FM; Burnett JR
J Clin Endocrinol Metab; 2015 Nov; 100(11):E1484-90. PubMed ID: 26323024
[TBL] [Abstract][Full Text] [Related]
18. Apolipoprotein B signal peptide and apolipoprotein E genotypes as determinants of the hepatic secretion of VLDL apoB in obese men.
Riches FM; Watts GF; van Bockxmeer FM; Hua J; Song S; Humphries SE; Talmud PJ
J Lipid Res; 1998 Sep; 39(9):1752-8. PubMed ID: 9741687
[TBL] [Abstract][Full Text] [Related]
19. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia.
Chan DC; Watts GF; Barrett PH; Beilin LJ; Redgrave TG; Mori TA
Diabetes; 2002 Aug; 51(8):2377-86. PubMed ID: 12145148
[TBL] [Abstract][Full Text] [Related]
20. Genetic determinants of apolipoprotein B-100 kinetics.
Ng TW; Ooi EM; Watts GF; Chan DC; Barrett PH
Curr Opin Lipidol; 2010 Apr; 21(2):141-7. PubMed ID: 20154610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
